Antibody Immunotherapies for Personalized Opioid Addiction Treatment
Eric H. Rosenn,
No information about this author
Miriam Korlansky,
No information about this author
Shahin Benyaminpour
No information about this author
et al.
Journal of Pharmacology and Experimental Therapeutics,
Journal Year:
2025,
Volume and Issue:
392(4), P. 103522 - 103522
Published: Feb. 25, 2025
Approved
therapies
for
managing
opioid
addiction
involve
intensive
treatment
regimens
which
remain
both
costly
and
ineffective.
As
pharmaceutical
interventions
have
achieved
variable
success
treating
substance
use
disorders
(SUD),
alternative
therapeutics
must
be
considered.
Antidrug
antibodies
induced
by
vaccination
or
introduced
as
monoclonal
antibody
formulations
can
neutralize
destroy
opioids
in
circulation
before
they
reach
their
central
nervous
system
targets
act
enzymes
to
deactivate
receptors,
preventing
the
physiologic
psychoactive
effects
of
substance.
A
lack
"reward"
those
suffering
from
SUD
has
been
shown
result
cessation
promote
long-term
abstinence.
Decreased
production
costs
advent
novel
gene
that
stimulate
vivo
renewed
interest
this
strategy.
Furthermore,
advances
understanding
immunopathogenesis
revealed
distinct
mechanisms
neuroimmune
dysregulation
underlying
disorder.
Beyond
assisting
with
drug
use,
could
treat
reverse
pathophysiologic
hallmarks
contribute
cause
chronic
cognitive
defects
resulting
use.
In
review,
we
synthesize
key
current
literature
regarding
efficacy
immunotherapies
SUD.
We
will
explore
neuropharmacology
these
treatments
relating
evidence
studies
on
counteract
various
behaviors
drawing
parallels
similar
immunopathology
observed
neurodegenerative
disorders.
Finally,
discuss
implications
immunization
technologies
application
computational
methods
developing
personalized
treatments.
SIGNIFICANCE
STATEMENT:
Significant
new
contributing
our
recently
emerged
leading
a
paradigm
shift
concerning
role
immunology
neuropathogenesis
Concurrently,
immunotherapeutic
such
advanced
capabilities
applications
take
advantage
principles.
This
article
reviews
antibody-based
being
studied
highlights
directions
further
research
may
management
Language: Английский
Transference and the psychological interplay in AI-enhanced mental healthcare
Frontiers in Psychiatry,
Journal Year:
2024,
Volume and Issue:
15
Published: Aug. 19, 2024
Citation:
Joseph
AP
and
Babu
A
(2024)
Transference
the
psychological
interplay
in
AI-enhanced
mental
healthcare.
Front.
Psychiatry
15:1460469.
doi:
10.3389/fpsyt.2024.1460469
Language: Английский
Acceptable Use Policies for Foundation Models
Kevin Klyman
No information about this author
Published: Nov. 26, 2024
Policymakers
hoping
to
regulate
foundation
models
have
focused
on
preventing
specific
objectionable
uses
of
AI
systems,
such
as
the
creation
bioweapons,
deepfakes,
and
child
sexual
abuse
material.
Effectively
blocking
these
can
be
difficult
in
case
they
are
general-purpose
technologies
that
principle
used
generate
any
type
content.
Nevertheless,
model
developers
been
proactive
this
area,
adopting
broad
acceptable
use
policies
prohibit
many
dangerous
select
themselves
part
their
terms
service
or
licenses.
As
2023
Foundation
Model
Transparency
Index,
researchers
at
Stanford
Center
for
Research
Models
catalogued
10
leading
developers.
All
companies
publicly
disclose
permitted,
restricted,
prohibited
models,
but
there
is
little
additional
information
available
about
how
implemented.
Only
3
enforce
policy,
while
only
2
give
justification
users
when
policy.
We
provide
background
a
preliminary
analysis
30
developers’
policies,
discussion
policy
considerations
related
attempts
restrict
models.
Language: Английский